FOLLOW US ON... FEEDBACK

Home >> Industry News >> International News
sideview vmo3D sideview vmo3D 30 day free trial
International News
  • Also available via:


EyeFocus Accelerator Launches In Berlin PDF
Submit Your News
International News
Friday, 14 November 2014

Eyefocus AcceleratorA new startup accelerator will be launched in Berlin this week. The accelerator, called The EyeFocus Accelerator, claims to be world's first accelerator focussed on eye care. It plans to invest up to 20,000 Euros into startups that are helping prevent, cure, and live with eye-disease and blindness, and is offering a 3 month accelerator program.

Globally, 280 million people are visually impaired and 39 million totally blind. 80% of eye disease can be cured, but innovation is needed to disrupt and improve how people diagnose, treat, and live with eye disease. EyeFocus aims to invest in and accelerates startups solving these eye care problems. The program provides startups with finance, mentoring, entrepreneurship education, product development, and ophthalmology support. The EyeFocus Accelerator is very focussed to only eye care and therefore able to offer targeted support for startups in this field. The program aims to building the eye care ecosystem, bringing together all the experts, investors, mentors, and companies in this space around the 12 week accelerator program.

The accelerator is being sponsored by Bayer Healthcare, Zeiss, and Peppermint Venture Partners and run a 3 month program in Berlin in the first quarter of 2015, with activities also in London.

 
09 October is World Sight Day 2014 PDF
Submit Your News
International News
Tuesday, 07 October 2014

World Sight Day 2014Nearly half a million Australians are blind or vision impaired. Amazingly, only three per cent access services that could make a significant difference to their health and livelihoods. Without low vision services, activities sighted people take for granted, such as shopping, gardening, preparing meals, crossing the road and catching public transport can be difficult and dangerous. Low vision services promote independence, are available throughout Australia, and are usually provided free of charge.

Many people with low vision don't know the benefits of accessing services that can equip them with the skills they need to maintain their independence throughout life and in a variety of settings including: home, work, school and sport.

2014 is the first year of the WHO GAP (Global Action Plan) and IAPB (International Agency for the Prevention of Blindness) encourages its members and partners to continue with its rolling theme: Universal Eye Health. This year, the 'Call to Action' for World Sight Day is: "No more Avoidable Blindness". The Call to Action will draw attention to a few key interventions that are crucial for the success of GAP's target – reducing avoidable blindness by 25%, by 2019. Using the call to action as a clarion call, organisations can identify various aspects of GAP that need urgent attention. They are also invited to customise the call to action, to their disease area – "No more Cataract" or "No more Trachoma" for example.

 
This Year's Silmo d'Or Winners Are... PDF
Submit Your News
International News
Monday, 29 September 2014

Silmo d'Or 2014CATEGORY « VISION »
BBGR with « Sirus Plus »

CATEGORY « MATERIAL / EQUIPMENT »
INTERACTIF VISUEL SYSTEME with « DEEP LIGHTS by Activisu »

CATEGORY « LOW VISION»
TELORION with « Telorion Zoom »

CATEGORY « CHILDREN »
CAROLINE ABRAM with « 5+5=10 » de Tête à Lunettes

CATEGORY « OPTIC FRAME »
LUCAS DE STAËL with « Stratus »

CATEGORY « SUNGLASS »
MASUNAGA X Kenzo Takada with « Campanule K18 »

CATEGORY « SPORT EQUIPMENT »
BOLLÉ Sport Protective with « Coverage » collection Enfant

CATEGORY « FRAME TECHNOLOGICAL INNOVATION »
MORGENROT EYEWEAR with « Morgenrot SC3 »

 
Eye Health Companies Form Industry Vision Group in UK PDF
Submit Your News
International News
Tuesday, 16 September 2014

Novartis, Bayer and Allergan are among the founding members of a new UK industry group that unites pharma and medical technology companies with an interest in eye health. The group is focused on overarching policy issues and aims to help secure greater prioritisation of eye health with policy makers and commissioners; and improve access to care, treatment and services for people with eye health conditions. The group is currently developing its work programme and looks forward to working collaboratively with the eye health community to make progress towards its stated aims.

Richard Marsh, chairman of the group, said: "I am delighted that both medical technology and pharmaceutical companies with an interest in eye health have come together to form this initiative. There is very little that is more precious to an individual than their eyesight and modern advances in medicine and medical technology means we have taken tremendous steps forward in helping to look after the eyes, and to tackle the causes of visual impairment.

"The IVG believes that the NHS (National Health Service) should give even greater priority to eye care and it is never more important to make this case than at a time when all services are under pressure. We will work both together as companies, and with other organisations representing both patients and practitioners, to ensure that the NHS has a vision for vision that embraces all the potential that medicine and medical technology can bring."

 
WCO Announces New Membership Categories PDF
Submit Your News
International News
Wednesday, 13 August 2014

The World Council of Optometry (WCO) has announced the launch of two new membership categories following their Governing Board meeting in Maputo last month. The two categories are 'Individual' and 'Corporate' membership. WCO has introduced these categories in order to make the organisation accessible to people who want to support their work.

Individual membership will be open to individual optometrists (as defined by WCO), vision scientists, faculty, researchers and eye care industry professionals. The cost of individual membership is US$100 and US$50 if the individual member is from a developing country.

Corporate memberships are open to commercial organisations that are not otherwise eligible for Associate or Affiliate membership and have a recognised and approved business relationship with an Associate, Affiliate or Individual member.

Individual and Corporate members must endorse the WCO concept of optometry and support WCO's vision and mission. The fee for Corporate membership is US$900 per annum.

Susan Cooper, President of The World Council of Optometry said: "We have created these new membership categories in order for us to grow our membership base while recognising and celebrating the support we have from individuals and organisations around the world. You do not have to be an optometrist to be interested in our mission is to promote eye health and vision care as a human right through advocacy, education and policy development. We look forward to welcoming new individuals and organisations to our membership body."

 
Major Fines for Roche and Novartis in Italy PDF
Submit Your News
International News
Tuesday, 03 June 2014

The Italian government is seeking EUR 1.2 billion in damages from drug companies Novartis and Roche for losses that it says the national health service incurred from the companies' efforts to restrict competition in ophthalmic drugs.

The Italian Health Ministry said that the two drugmakers colluded to direct patients with an eye disorder to a more expensive medicine. That resulted in damages to the Italian health system of EUR 45 million in 2012, EUR 540 million last year and EUR 615 million this year, the ministry said.

The move comes after the Italian antitrust authorities in March fined the two Swiss pharmaceutical companies a combined EUR 180 million in the same case, having found that they colluded to keep doctors from prescribing a relatively inexpensive eye treatment in favor of a more expensive drug used to treat a common cause of blindness. The authorities said in March: "The companies colluded to exclude the cheap drug Avastin, used in the treatment of the most common eyesight condition in the elderly as well as other serious sight problems, and channel demand towards the much more expensive drug Lucentis, through an artificial distinction between the two products. The anticompetitive agreement caused the Italian National Health Service to sustain additional expenses estimated at over EUR 45 million in 2012, while increased future costs might exceed EUR 600 million per year. Novartis and Roche were imposed fines totaling respectively EUR 92 and 90,5 million."

It is expected that other countries in Europe, such as France, will follow suit.

 
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>

Page 1 of 51